Treatment with poly (ADP-ribose) polymerase (PARP) inhibitor (L-2286) reduces this intense phosphorylation to activate GSK-3β, which significantly reduces post-infarction cardiac hypertrophy and interstitial fibrosis, thereby ameliorating the progression of heart failure 85. The gene discussed is GSK3B; the disease is heart failure.